Automate Your Wheel Strategy on DNA
With Tiblio's Option Bot, you can configure your own wheel strategy including DNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DNA
- Rev/Share 4.377
- Book/Share 11.936
- PB 0.718
- Debt/Equity 0.6712
- CurrentRatio 4.8807
- ROIC -0.3993
- MktCap 501618134.0
- FreeCF/Share -6.366
- PFCF -1.4527
- PE -0.9847
- Debt/Assets 0.336
- DivYield 0
- ROE -0.6306
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2025 Results Conference Call May 6, 2025 5:00 PM ET Company Participants Daniel Marshall - Sr. Manager, Communications and Ownership Jason Kelly - Co-Founder and Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Mark Massaro - BTIG Tejas Savant - Morgan Stanley Evie Koslosky - Goldman Sachs Matt Larew - William Blair Brendan Smith - TD Cowen Operator [Call Starts Abruptly] live on air. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.
Read More
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to loss of $3.20 per share a year ago.
Read More
Ginkgo Bioworks Reports First Quarter 2025 Financial Results
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON , May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at …
Read More
Phytolon and Ginkgo Bioworks Boost Natural Food Colors by Hitting Full-Project Milestone, Nearly Tripling the Manufacturing Efficiency of Phytolon's Innovative Colors
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral
Replacing artificial dyes with natural colors has become a national priority, moved by consumer demand, regulation, and governmental pressure. Achieving this milestone—by increasing coloring efficiency and reducing costs—could unlock new market segments that are not well-supported by current natural food colors.
Read More
Ginko Automation Partners with Aura Genetics to Accelerate Direct-to-Consumer Testing and Innovation
Published: April 22, 2025 by: PRNewsWire
Sentiment: Neutral
BOSTON , April 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a Reconfigurable Automation Cart (RAC) system to Aura Genetics, a high-complexity diagnostic laboratory servicing the growing at-home testing and wellness market. This advanced modular laboratory automation platform will be deployed at Aura Genetics' new 22,000-square-foot high-throughput facility at the UPS Healthcare Labport, located at the end of the runway at the Louisville, KY airport.
Read More
Plex Research Partners With Ginkgo Bioworks on Artificial Intelligence (AI)-Powered Drug Discovery to Identify Novel Disease Mechanisms and Pathways
Published: April 03, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Plex Research is partnering with Ginkgo Bioworks to use AI to deepen understanding of the mechanisms of action of existing drugs.
Read More
Ginkgo Bioworks (DNA) Upgraded to Buy: Here's Why
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2024 Earnings Call Transcript
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q4 2024 Earnings Conference Call February 25, 2025 5:30 PM ET Company Participants Joseph Fridman - Director, Communications and Corporate Affairs Jason Kelly - Founder, CEO & Director Mark Dmytruk - CFO Jason Kelly - Founder, CEO & Director Conference Call Participants Jason Lai - Morgan Stanley Evie Kslosky - Goldman Mark Massaro - BTIG Brendan Smith - TD Cowen Matt Larew - William Blair & Company Joseph Fridman Good evening. I'm Joseph Fridman, Director of Communications and Corporate Affairs here at Ginkgo, where it's my fifth year.
Read More
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Negative
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $3.60 per share a year ago.
Read More
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target Cell Engineering revenue of $35 million in the fourth quarter of 2024, representing 29% growth over 2023 BOSTON , Feb. 25, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2024. The update, including a webcast slide presentation with additional details on the fourth quarter and full year, …
Read More
Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
BOSTON , Feb. 21, 2025 /PRNewswire/ -- Volta Labs , a leading genomics applications company, and Ginkgo Bioworks, (NYSE: DNA), which is building a leading platform for cell programming and biosecurity, today announced the integration of the Callisto™ Sample Prep System at Ginkgo Bioworks as part of the routine Illumina sequencing workflow. "I like the Apps and the App Store concept on Callisto.
Read More
Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
International consortium to develop rapid metagenomic NGS solutions that can identify known and novel respiratory pathogens, reduce time-to-diagnosis, and enhance hospital decision-making and public health preparedness BOSTON , Feb. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a collaboration with the European Health and Digital Executive Agency (HaDEA) as contracting authority under a joint tender of up to €24 million. The funding is made available through the EU4Health programme, linked to the key priorities of the Health Emergency Preparedness and Response Authority (HERA) of the European Commission.
Read More
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2024 Results Presentation
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral
Presentation and Q&A session scheduled for post-market on Tuesday, February 25, 2025 BOSTON , Feb. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2024, on Tuesday, February 25, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
Read More
About Ginkgo Bioworks Holdings, Inc. (DNA)
- IPO Date 2021-04-19
- Website https://www.ginkgobioworks.com
- Industry Biotechnology
- CEO Dr. Jason Kelly Ph.D.
- Employees 834